[CytoReason in GlobeNewswire] CytoReason to license its IBD disease model to Sanofi in expanded multiyear, multimillion dollar deal

[CytoReason in GlobeNewswire] CytoReason to license its IBD disease model to Sanofi in expanded multiyear, multimillion dollar deal

Source Node: 1917760

Collaboration will support Sanofi’s use of CytoReason’s computational disease models to develop new targets for inflammatory bowel disease (IBD).

Read more here.

Time Stamp:

More from OurCrowd Blog